VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+L…
Category: News
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce une avancée majeure dans son nouveau partenariat de fabrication avec Catalent
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les mala…
Omidenepag Promising Against Glaucoma in Real-World Study
Eye drops containing 0.002% omidenepag isopropyl can safely reduce intraocular pressure in patients with newly diagnosed primary open-angle glaucoma, according to a real-world study. Medscape Medical News
Age Ups Risk for Acute Dacryocystitis in Blocked Tear Ducts
Acute dacryocystitis is common in women, and the risk for the condition rises with age, especially in those with primary acquired nasolacrimal duct obstruction. Medscape Medical News
Tap Water Rinses: A Recipe for Amoebic Keratitis
Wearing contact lenses overnight and failing to change the case can increase your risk for infectious keratitis by 10-fold, warns a new study. Medscape News UK
Sudden Vision Loss May Be a Cardiovascular Red Flag
From atrial fibrillation to hypertension, common cardiovascular risks may manifest in the eyes — highlighting the need for cardiology-ophthalmology teamwork. Medscape
Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be pres…
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
Alcon annonce l’arrivée de Clareon PanOptix Pro au Canada, une lentille intraoculaire réduisant la dispersion de la lumière comme aucune autre LIO trifocale
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires dédié à aider les gens à voir avec clarté, a annoncé aujourd’hui l’approbation de la lentille intraoculaire (LIO) ClareonMD PanOptix MD Pro pour les…
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO–(BUSINESS WIRE)– #AlconCanada–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. Pa…
Intensive Bevacizumab Boosts Vision in Macular Degeneration
Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real-world study from the Netherlands shows. Medscape Medica…
Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
Comorbidities Intensify Rare Neurologic Diseases
Cardiovascular and autoimmune comorbidities often occur in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Medscape News UK
Review of Uveitis Underscores Urgency of Early Action
A JAMA review has urged earlier recognition and treatment of uveitis, a major cause of preventable blindness, with practical advice for clinicians. Medscape UK
Blind Spots: Comparing the Vision Costs of Weight-Loss Drugs
Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects. Medscape Medical News
Leflunomide, HCQ Combo Effects Validated in Sjögren Disease
The combination of leflunomide and hydroxychloroquine outperformed placebo in reducing disease activity in primary Sjögren syndrome in a second phase II study. Medscape Medical News
Sightview Names Tycene Fritcher as CEO
DURHAM, N.C.–(BUSINESS WIRE)– #EHR–Sightview, the only electronic health record and practice management partner focused solely on eyecare, has named Tycene Fritcher as CEO.
European Behçet’s Recommendations Forthcoming
When to use apremilast and biologics and how to deal with vascular involvement were some of the main areas to be updated in forthcoming EULAR recommendations for Behçet’s disease. Medscape Medical News
Time to Monitor Serum Hydroxychloroquine Levels in Lupus?
Monitoring serum hydroxychloroquine levels could help to ensure that patients with SLE are being treated with the drug optimally, study findings suggest. Medscape Medical News